This verbiage was in the PR today: In addition
Post# of 36537
In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.
(I was under the impression than they sold off or closed all the pharmacies.)
Has any of the acquisitions resulted in any sales or revenues? I guess we will see Tuesday.